Posted by Michael Wonder on 24 Nov 2020
PolyPid granted breakthrough therapy designation from FDA for D-PLEX for the prevention of surgical site infections in colorectal surgery
24 November 2020 - PolyPid Ltd today announced that D-PLEX100 has received breakthrough therapy designation from the U.S. FDA for the prevention of surgical site infections in patients undergoing elective colorectal surgery.
The breakthrough therapy designation for D-PLEX100 is based on conclusive positive results from a Phase 2 clinical trial evaluating D-PLEX100 for the prevention of surgical site infections in abdominal colorectal surgery.
